Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
about
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts.Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer.The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
P2860
Q30586073-37BD0B12-C413-46A9-A071-41F3F5E22790Q34794205-A78723BC-3E2C-4C8D-840B-5DFA46A4C0F6Q36048716-EDA3BB5C-F0DD-42A1-A8B0-F95C5502A78DQ36315170-FBFA11B4-7A8C-413C-86A4-8BC2FE3A444CQ37342222-E85F325B-51EC-47FC-B440-7E882738A3D8Q37460247-BA03909C-2E09-422E-B61B-066BB4113CD7Q38116790-1D4B1D90-CF80-4D46-8E96-4A77C4D146EBQ38134295-F789606C-EA65-4034-A3DD-1A1F5FB383AEQ38271894-74EDEA1A-FA8E-471C-99CD-74046543C46CQ44534598-F038A275-F543-45B2-AD23-17DA5214E234Q46202988-32D19B8A-639A-428A-B0DE-EC0EE3EF5B14Q46874421-5414BE7E-96D8-4CEC-B8ED-DBA912FF42E0Q52985554-4F853B3E-9819-4851-B958-66E236C11C0F
P2860
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Implications of prostate-speci ...... n therapy for prostate cancer.
@ast
Implications of prostate-speci ...... n therapy for prostate cancer.
@en
type
label
Implications of prostate-speci ...... n therapy for prostate cancer.
@ast
Implications of prostate-speci ...... n therapy for prostate cancer.
@en
prefLabel
Implications of prostate-speci ...... n therapy for prostate cancer.
@ast
Implications of prostate-speci ...... n therapy for prostate cancer.
@en
P2093
P1433
P1476
Implications of prostate-speci ...... n therapy for prostate cancer.
@en
P2093
Alberto Bossi
Laurence Collette
Massimo Maffezzini
P304
605-13; discussion 613
P356
10.1016/J.EURURO.2006.10.062
P407
P577
2006-11-13T00:00:00Z